15 results on '"Haas HS"'
Search Results
2. Analyzing the Psychological and Social Contents of Evidence-Experimental Comparison between Guessing, Naturalistic Observation, and Systematic Analysis.
- Author
-
Haas HS, Pisarzewska Fuerst M, Tönz P, and Gubser-Ernst J
- Abstract
To improve inferences about psychological and social evidence contained in pictures and texts, a five-step algorithm-Systematic Analysis (SA)-was devised. It combines basic principles of interpretation in forensic science, providing a comprehensive record of signs of evidence. Criminal justice professionals evaluated the usefulness of SA. Effects of applying SA were tested experimentally with 41 subjects, compared to 39 subjects observing naturally (naturalistic observation) and 47 subjects guessing intuitively intuitive guessing group. After being trained in SA, prosecutors and police detectives (N = 217) attributed it a good usefulness for criminal investigation. Subjects (graduate students) using SA found significantly more details about four test cases than those observing naturally (Cohen's d = 0.58). Subjects who learned SA well abducted significantly better hypotheses than those who observed naturally or who guessed intuitively. Internal validity of SA was α = 0.74. Applying SA improved observation significantly and reduced confirmation bias., (© 2015 American Academy of Forensic Sciences.)
- Published
- 2015
- Full Text
- View/download PDF
3. The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT.
- Author
-
Fuchs R, Schwach G, Stracke A, Meier-Allard N, Absenger M, Ingolic E, Haas HS, Pfragner R, and Sadjak A
- Subjects
- Antihypertensive Agents pharmacology, Cell Line, Tumor drug effects, Drug Screening Assays, Antitumor, Humans, Receptors, Adrenergic, alpha-1 metabolism, Antineoplastic Agents pharmacology, Apoptosis drug effects, Carcinoma, Medullary drug therapy, Prazosin pharmacology, Thyroid Neoplasms drug therapy
- Abstract
Background/aim: Medullary thyroid carcinoma (MTC) is a tumor associated with poor prognosis since it exhibits high resistance against conventional cancer therapy. Recent studies have shown that quinazolines exhibit a pro-apoptotic effect on malignant cells. The aim of the present study was to elucidate whether MTC cells are affected by quinazolines, in particular prazosin., Materials and Methods: Proliferation, apoptosis and cell morphology of the MTC cell line TT were analyzed by WST-1 assay, caspase 3/7 activation tests and microscopy. Fibroblasts were used as control for non-malignant cells., Results: Prazosin potently inhibited the growth of TT cells, induced apoptosis and caused vacuolization, as well as needle-like filopodia. Fibroblasts were affected by prazosin in the same way as MTC cells., Conclusion: MTC cells are responsive to prazosin treatment similar to other malignancies. The fact that fibroblasts also respond to prazosin further highlights the importance to identify the unknown pro-apoptotic target of quinazolines., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2015
4. The influence of glutamate receptors on proliferation and metabolic cell activity of neuroendocrine tumors.
- Author
-
Haas HS, Pfragner R, Tabrizi-Wizsy NG, Rohrer K, Lueftenegger I, Horwath C, Allard N, Rinner B, and Sadjak A
- Subjects
- Animals, Humans, Neuroendocrine Tumors pathology, Receptors, Glutamate metabolism, Antineoplastic Agents therapeutic use, Cell Proliferation drug effects, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors metabolism, Receptors, Glutamate chemistry
- Abstract
Neuroendocrine tumors are relatively insensitive to radiation therapy, as well as chemotherapy. Thus, new approaches for alternative therapies are needed. We found that glutamate receptor antagonists are capable of suppressing tumor growth and cell activity of different peripheral malignancies. In the present article we review scientific literature in this field of science. Subtype-specific, non-competitive, metabotropic glutamate receptor-1 antagonists differently suppressed the growth and metabolic cell activity of one human medullary thyroid carcinoma cell line, as well as of four different human midgut neuroendocrine tumor cell lines. Furthermore, PCR analyses revealed that this subtype of glutamate receptor is expressed in these cell lines. These first results indicate that specific metabotropic glutamate receptor antagonists suppress the proliferation and cell activity of neuroendocrine tumor cells, which makes them possible targets in cancer therapy.
- Published
- 2013
5. α1-adrenergic drugs exhibit affinity to a thapsigargin-sensitive binding site and interfere with the intracellular Ca2+ homeostasis in human erythroleukemia cells.
- Author
-
Fuchs R, Schraml E, Leitinger G, Letofsky-Papst I, Stelzer I, Haas HS, Schauenstein K, and Sadjak A
- Subjects
- Adrenergic alpha-1 Receptor Agonists pharmacology, Adrenergic alpha-1 Receptor Antagonists pharmacology, Aging drug effects, Binding Sites drug effects, Cell Death drug effects, Cell Differentiation drug effects, Cell Line, Tumor, Cell Survival drug effects, Humans, K562 Cells, Membrane Potential, Mitochondrial drug effects, Mitochondria drug effects, Mitochondrial Membranes drug effects, Mitochondrial Membranes metabolism, Naphazoline pharmacology, Reactive Oxygen Species metabolism, Receptors, Adrenergic, alpha-1 metabolism, Sarcoplasmic Reticulum Calcium-Transporting ATPases antagonists & inhibitors, Sarcoplasmic Reticulum Calcium-Transporting ATPases metabolism, Adrenergic Agents pharmacology, Calcium metabolism, Homeostasis drug effects, Leukemia, Erythroblastic, Acute drug therapy, Leukemia, Erythroblastic, Acute metabolism, Thapsigargin pharmacology
- Abstract
Even though the erythroleukemia cell lines K562 and HEL do not express α1-adrenoceptors, some α1-adrenergic drugs influence both survival and differentiation of these cell lines. Since Ca2+ is closely related to cellular homeostasis, we examined the capacity of α1-adrenergic drugs to modulate the intracellular Ca2+ content in K562 cells. Because of morphological alterations of mitochondria following α1-adrenergic agonist treatment, we also scrutinized mitochondrial functions. In order to visualize the non-adrenoceptor binding site(s) of α1-adrenergic drugs in erythroleukemia cells, we evaluated the application of the fluorescent α1-adrenergic antagonist BODIPY® FL-Prazosin. We discovered that the α1-adrenergic agonists naphazoline, oxymetazoline and also the α1-adrenergic antagonist benoxathian are able to raise the intracellular Ca2+-content in K562 cells. Furthermore, we demonstrate that naphazoline treatment induces ROS-formation as well as an increase in Δψm in K562 cells. Using BODIPY® FL-Prazosin we were able to visualize the non-adrenoceptor binding site(s) of α1-adrenergic drugs in erythroleukemia cells. Interestingly, the SERCA-inhibitor thapsigargin appears to interfere with the binding of BODIPY® FL-Prazosin. Our data suggest that the effects of α1-adrenergic drugs on erythroleukemia cells are mediated by a thapsigargin sensitive binding site, which controls the fate of erythroleukemia cells towards differentiation, senescence and cell death through modulation of intracellular Ca2+., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
6. α1-Adrenergic drugs modulate differentiation and cell death of human erythroleukemia cells through non adrenergic mechanism.
- Author
-
Fuchs R, Schraml E, Leitinger G, Stelzer I, Allard N, Haas HS, Schauenstein K, and Sadjak A
- Subjects
- Adrenergic alpha-Agonists pharmacology, Adrenergic alpha-Antagonists pharmacology, Apoptosis drug effects, Autophagy drug effects, Caspase 3 metabolism, Cell Aggregation drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Drug Interactions, Erythroid Cells cytology, Erythroid Cells metabolism, Erythroid Precursor Cells cytology, Erythroid Precursor Cells drug effects, Erythroid Precursor Cells metabolism, Fetal Blood cytology, Gene Expression drug effects, Gene Expression genetics, Glycophorins metabolism, Hemin pharmacology, Hemoglobins metabolism, Humans, Hydrogen-Ion Concentration drug effects, K562 Cells, Leukemia, Erythroblastic, Acute metabolism, Leukocyte Common Antigens metabolism, Megakaryocyte Progenitor Cells cytology, Megakaryocyte Progenitor Cells drug effects, Megakaryocyte Progenitor Cells metabolism, Megakaryocytes cytology, Naphazoline pharmacology, Necrosis chemically induced, Oxathiins pharmacology, Prazosin pharmacology, Receptors, Adrenergic, alpha-1 genetics, Adrenergic alpha-1 Receptor Agonists pharmacology, Cell Death drug effects, Cell Differentiation drug effects, Leukemia, Erythroblastic, Acute pathology
- Abstract
Preliminary data showed that α1-adrenergic antagonists induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells. To test the hypothesis whether survival and differentiation of erythroleukemia cells are under control of α1-adrenergic signalling, we examined α1-adrenoceptor expression of erythroleukemia cells and compared the in vitro effects of α-adrenergic antagonists with those of agonists. We discovered that α1-adrenergic agonists suppress both erythroid differentiation and growth of erythroleukemia cells concomitant with lipofuscin accumulation, autophagy and necrotic cell death. α1-adrenergic agonists also inhibit the in vitro growth of physiologic hematopoietic progenitors obtained from umbilical cord blood with high selectivity for the erythroid lineage. Interestingly, the observed effects could not be related to α1-adrenoceptors, even though agonists and antagonists displayed opposing effects regarding cellular growth and differentiation of erythroleukemia cells. Our data suggest that the effects of α1-adrenergic drugs are related to a non-adrenoceptor binding site, controlling the fate of erythroid progenitor cells towards differentiation and cell death. Since the observed effects are not mediated through adrenoceptors, the physiologic relevance of our data remains unclear, so far. Nevertheless, the identification of the still unknown binding site(s) might disclose new insights into regulation of erythroid differentiation and cell death., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
7. Peripheral glutamate signaling in head and neck areas.
- Author
-
Haas HS, Linecker A, Pfragner R, and Sadjak A
- Subjects
- Animals, Cell Proliferation drug effects, Glutamic Acid metabolism, Head and Neck Neoplasms pathology, Humans, Oral Surgical Procedures, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Receptors, N-Methyl-D-Aspartate physiology, Salivary Glands innervation, Salivary Glands metabolism, Skin metabolism, Taste physiology, Taste Buds metabolism, Thyroid Gland metabolism, Excitatory Amino Acid Antagonists pharmacology, Head and Neck Neoplasms metabolism, Receptors, Glutamate physiology, Signal Transduction physiology
- Abstract
The major excitatory neurotransmitter glutamate is also found in the periphery in an increasing number of nonexcitable cells. In line with this it became apparent that glutamate can regulate a broad array of peripheral biological responses, as well. Of particular interest is the discovery that glutamate receptor reactive reagents can influence tumor biology. However, the knowledge of glutamate signaling in peripheral tissues is still incomplete and, in the case of head and neck areas, is almost lacking. The roles of glutamate signaling pathways in these regions are manifold and include orofacial pain, periodontal bone production, skin and airway inflammation, as well as salivation. Furthermore, the interrelations between glutamate and cancers in the oral cavity, thyroid gland, and other regions are discussed. In summary, this review shall strengthen the view that glutamate receptor reagents may also be promising targets for novel therapeutic concepts suitable for a number of diseases in peripheral tissues. The contents of this review cover the following sections: Introduction; The "Glutamate System"; The Taste of Glutamate; Glutamate Signaling in Dental Regions; Glutamate Signaling in Head and Neck Areas; Glutamate Signaling in Head and Neck Cancer; A Brief Overview of Glutamate Signaling in Other Cancers; and Conclusion.
- Published
- 2010
- Full Text
- View/download PDF
8. The alpha1-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells.
- Author
-
Fuchs R, Stelzer I, Haas HS, Leitinger G, Schauenstein K, and Sadjak A
- Subjects
- Adrenergic alpha-Antagonists pharmacology, Cell Line, Tumor, Erythroid Cells, Humans, K562 Cells, Leukemia, Erythroblastic, Acute pathology, Apoptosis drug effects, Cell Differentiation drug effects, Leukemia, Erythroblastic, Acute drug therapy, Megakaryocytes cytology, Oxathiins pharmacology, Prazosin pharmacology, Receptors, Adrenergic, alpha-1 metabolism
- Abstract
The erythroleukemia cell lines K562 and human erythroleukemia (HEL) are established models to study erythroid and megakaryocytic differentiation in vitro. In this study, we show that the alpha1-adrenergic antagonists, benoxathian and prazosin, inhibit the proliferation and induce apoptosis in K562 and HEL cells. Furthermore, both tested substances induced the expression of the megakaryocytic marker CD41a, whereas the expression of the erythroid marker glycophorin-a was decreased or unchanged. Even though the expression of differentiation markers was similar after benoxathian and prazosin treatment in both cell lines, endomitosis of erythroleukemia cells was observed only after prazosin treatment. So far, benoxathian and prazosin are the first described extracellular ligands, which cause megakaryocytic differentiation in K562 and HEL cells. In summary, these results indicate a possible role of alpha1-adrenergic receptor signaling in the regulation of erythroid and megakaryocytic differentiation, even though the receptor dependence of the observed effects needs further investigation.
- Published
- 2009
- Full Text
- View/download PDF
9. The non-competitive metabotropic glutamate receptor-1 antagonist CPCCOEt inhibits the in vitro growth of human melanoma.
- Author
-
Haas HS, Pfragner R, Siegl V, Ingolic E, Heintz E, Schraml E, and Schauenstein K
- Subjects
- Antineoplastic Agents pharmacology, Cell Proliferation drug effects, Docetaxel, Glutamic Acid metabolism, Humans, Melanoma ultrastructure, Skin Neoplasms ultrastructure, Taxoids pharmacology, Tumor Cells, Cultured, Chromones pharmacology, Drug Resistance, Neoplasm drug effects, Excitatory Amino Acid Antagonists pharmacology, Melanoma metabolism, Receptors, Metabotropic Glutamate antagonists & inhibitors, Skin Neoplasms metabolism
- Abstract
Five decades ago, the dicarboxylic amino acid glutamate became recognized as the major excitatory neurotransmitter in the central nervous system. In recent years, the expression of glutamate receptors was detected also in peripheral, non-neuronal tissues. Furthermore, it was found that glutamate stimulated the proliferation and migration of several peripheral tumor cells, and that glutamate receptor antagonists limited tumor growth. Most of these studies, however, used broad spectrum compounds and/or group-specific antagonists. Here we report that a selective, non-competitive metabotropic glutamate receptor-1 antagonist, CPCCOEt (7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester), significantly inhibited the proliferation and modified the morphology of two human melanoma cell lines. These effects were independent of the external glutamate level in the culture medium. In addition, CPCCOEt significantly enhanced the tumoricidal effects of cytostatic drugs. Thus, selective non-competitive metabotropic glutamate receptor antagonists may be used alone and/or with the synergistic effects of chemotherapy, thus enhancing existing therapies of melanoma and possibly other malignancies.
- Published
- 2007
10. Glutamate receptor-mediated effects on growth and morphology of human histiocytic lymphoma cells.
- Author
-
Haas HS, Pfragner R, Siegl V, Ingolic E, Heintz E, and Schauenstein K
- Subjects
- 6-Cyano-7-nitroquinoxaline-2,3-dione pharmacology, Cell Shape drug effects, Culture Media, Serum-Free pharmacology, Excitatory Amino Acid Agonists pharmacology, Excitatory Amino Acid Antagonists pharmacology, Glutamine pharmacology, Humans, Kainic Acid pharmacology, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse ultrastructure, Microscopy, Electron, Time Factors, U937 Cells, alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid pharmacology, Cell Proliferation drug effects, Glutamic Acid pharmacology, Receptors, Glutamate physiology
- Abstract
Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) and binds to a variety of receptors, which recently have also been detected in peripheral, non-excitable cells. New research suggests that this abundant amino acid might also be involved in the growth of tumor cells acting via novel receptor-mediated autocrine/paracrine signal transduction pathways. We report here that glutamate, as well as glutamate receptor reactive drugs, differentially modulate growth and morphology of human histiocytic lymphoma-derived U937 cells. These effects were different depending on the culture milieu: in glutamine-free medium the glutamate receptor agonists, kainate (KA), and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), but also the antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), significantly decreased the proliferation of U937 cells. In contrast, in cultures devoid of glutamate, glutamine and serum, the agonists significantly increased cell proliferation whereas the antagonist CNQX showed no effect. These data point to a significant role of peripheral glutamate receptors in tumor cell proliferation.
- Published
- 2005
11. Immunity, hormones, and the brain.
- Author
-
Haas HS and Schauenstein K
- Subjects
- Animals, Humans, Brain immunology, Hormones immunology, Immunity immunology
- Published
- 2001
- Full Text
- View/download PDF
12. Twenty-year follow-up of antenatal corticosteroid treatment.
- Author
-
Dessens AB, Haas HS, and Koppe JG
- Subjects
- Adult, Cognition, Educational Status, Female, Follow-Up Studies, Genital Diseases, Female etiology, Genital Diseases, Male etiology, Growth, Health Status, Humans, Infant, Newborn, Intelligence, Male, Pregnancy, Randomized Controlled Trials as Topic, Reproduction, Respiratory Distress Syndrome, Newborn prevention & control, Sexual Dysfunctions, Psychological etiology, Socioeconomic Factors, Anti-Inflammatory Agents adverse effects, Betamethasone adverse effects, Prenatal Exposure Delayed Effects
- Abstract
Objective: To study late side effects of antenatal corticosteroid treatment on health and sexual development in subjects 20 to 22 years old., Methods: A follow-up study among young adults whose mothers had, because of a threatening delivery, participated in a randomized, double-blind, placebo- controlled trial of betamethasone to prevent neonatal respiratory distress syndrome. Measurements were taken on general health, growth, development in puberty, reproductivity, genital or gynecological complaints, gender development, sexual orientation, sex-specific cognitive functioning, and psychoneuroticism. In addition, some measurements were performed on family diseases, socioeconomic status, and education., Results: No differences were found between the corticosteroid-treated and placebo groups as to medical or psychological variables. In general, the subjects were healthy and had normal intellectual capacities. Groups did not differ on gender development, sexual orientation, sex-specific cognitive functioning, and psychoneuroticism. Systolic blood pressure was significantly lower in the corticosteroid group, but the groups did not differ as to diastolic blood pressure., Conclusions: Our 20-year follow-up study indicates that 1 course of antenatally administered corticosteroid to prevent respiratory distress syndrome does not have adverse effects up to adulthood.
- Published
- 2000
- Full Text
- View/download PDF
13. The dialogue between the brain and immune system involves not only the HPA-axis.
- Author
-
Schauenstein K, Rinner I, Felsner P, Liebmann P, Haas HS, Wölfler A, Stevenson R, Westermann J, Cohen RL, and Chambers DA
- Subjects
- Acetylcholine immunology, Animals, Autonomic Nervous System physiopathology, Catecholamines physiology, Feedback physiology, Humans, Lymphocyte Activation immunology, Mice, Rats, Autoimmune Diseases immunology, Brain physiopathology, Hypothalamo-Hypophyseal System physiopathology, Pituitary-Adrenal System physiopathology
- Abstract
Starting out from our previous observations that defects in the immune system-brain feedback predispose to pathogenic immune responses, our interest focuses at the roles of adrenergic/cholinergic neurotransmitters in brain-immune interactions. We have shown in rodent models that 1) both catecholamines and acetylcholine are potent modulators of peripheral immune functions, 2) cholinergic signals are involved in the afferent signalling of the immune system, and 3) lymphocytes not only express functional adrenergic and cholinergic receptors, but synthesize and release neurotransmitters, such as acetylcholine, in quantitative dependence of differentiation and activation. Studies are presently being initiated to investigate the role(s) of these non-neuronal neurotransmitters within immune tissues, and to explore the relevance of excitatory amino acids as important central neurotransmitters in the brain-immune system dialogue.
- Published
- 2000
- Full Text
- View/download PDF
14. In vivo immunomodulation by peripheral adrenergic and cholinergic agonists/antagonists in rat and mouse models.
- Author
-
Schauenstein K, Felsner P, Rinner I, Liebmann PM, Stevenson JR, Westermann J, Haas HS, Cohen RL, and Chambers DA
- Subjects
- Animals, Cholinergic Fibers physiology, Mice, Rats, Receptors, Adrenergic physiology, Autonomic Nervous System physiology, Immune System physiology, Neuroimmunomodulation
- Abstract
Our work is devoted to defining relationships between the immune system and the adrenergic and cholinergic systems in vivo. In the rat model, we have shown that the cells of different immune compartments express the genes of a defined set of adrenergic/cholinergic receptors, and it was shown that lymphocytes are a site of non-neuronal production of norepinephrine and acetylcholine. Furthermore, using implantable slow-release tablets containing adrenergic or cholinergic agonists/antagonists, distinct and partly opposite effects were observed on peripheral immune functions. Concerning sympathetic immunoregulation, our data--in contrast to those of other studies--suggest that an enhanced adrenergic tonus leads to immunosuppression primarily via alpha 2-receptor-mediated mechanisms. Beta-blockade strongly enhances this effect, most likely by inhibition of pineal melatonin synthesis. In recent experiments on the kinetics it was found that the continuous alpha-adrenergic treatment entails a strong suppression of cellular responsiveness during the first few hours, which is increasingly followed by a general loss of lymphocytes in blood and lymphoid organs most likely due to enhanced apoptosis. More recently, we have extended our studies to the mouse model. First data obtained with RNAse protection assays suggest a biphasic effect on the gene expression of several cytokines in spleen cells due to adrenergic in vivo treatment.
- Published
- 2000
- Full Text
- View/download PDF
15. Neuroimmunomodulation via limbic structures--the neuroanatomy of psychoimmunology.
- Author
-
Haas HS and Schauenstein K
- Subjects
- Humans, Limbic System anatomy & histology, Limbic System immunology, Neuroimmunomodulation physiology
- Abstract
During the last 20 years, mutual communications between the immune, the endocrine and the nervous systems have been defined on the basis of physiological, cellular, and molecular data. Nevertheless, a major problem in the new discipline "Psychoneuroimmunology" is that controversial data and differences in the interpretation of the results make it difficult to obtain a comprehensive overview of the implications of immunoneuroendocrine interactions in the maintenance of physiological homeostasis, as well as in the initiation and the course of pathological conditions within these systems. In this article, we will first discuss the afferent pathways by which immune cells may affect CNS functions and, conversely, how neural tissues can influence the peripheral immune response. We will then review recent data, which emphasize the (patho)physiological roles of hippocampal-amygdala structures and the nucleus accumbens in neuroimmunomodulation. Neuronal activity within the hippocampal formation, the amygdaloid body, and the ventral parts of the basal ganglia has been examined most thoroughly in studies on neuroendocrine, autonomic and cognitive functions, or at the level of emotional and psychomotor behaviors. The interplay of these limbic structures with components of the immune system and vice versa, however, is still less defined. We will attempt to review and discuss this area of research taking into account recent evidences for neuroendocrine immunoregulation via limbic neuronal systems, as well as the influence of cytokines on synaptic transmission, neuronal growth and survival in these brain regions. Finally, the role of limbic structures in stress responses and conditioning of immune reactivity will be commented. Based on these data, we propose new directions of future research.
- Published
- 1997
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.